Navidea Biopharmaceuticals Inc banner

Navidea Biopharmaceuticals Inc
OTC:NAVB

Watchlist Manager
Navidea Biopharmaceuticals Inc Logo
Navidea Biopharmaceuticals Inc
OTC:NAVB
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: $10k

Multiples-Based Value

There is not enough data to reliably calculate the multiples-based value of NAVB.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NAVB Multiples-Based Value
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

NAVB Competitors Multiples
Navidea Biopharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Navidea Biopharmaceuticals Inc
OTC:NAVB
4.6m USD 0 -3.9 -0.3 -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
368.4B USD 6 88 14.6 20.3
US
Amgen Inc
NASDAQ:AMGN
191.5B USD 5.2 24.8 14.4 14.4
US
Gilead Sciences Inc
NASDAQ:GILD
170.8B USD 5.8 20.1 12.6 15.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.3 28.3 21.3 22.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD 5.5 17.6 13.1 14.9
NL
argenx SE
XBRU:ARGX
44.4B EUR 12.5 40.2 43.6 44.6
AU
CSL Ltd
ASX:CSL
66.1B AUD 2.9 32.4 10.9 13.7
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Navidea Biopharmaceuticals Inc
OTC:NAVB
Average P/S: 3 369 303.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
5%
1.2
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.3
11%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.6
NL
argenx SE
XBRU:ARGX
12.5
28%
0.4
AU
CSL Ltd
ASX:CSL
2.9
4%
0.7
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Navidea Biopharmaceuticals Inc
OTC:NAVB
Average P/E: 35.9
Negative Multiple: -3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.8
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.1
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.3
19%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
14%
1.3
NL
argenx SE
XBRU:ARGX
40.2
30%
1.3
AU
CSL Ltd
ASX:CSL
32.4
9%
3.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Navidea Biopharmaceuticals Inc
OTC:NAVB
Average EV/EBITDA: 18.6
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.6
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
9%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.3
18%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
17%
0.8
NL
argenx SE
XBRU:ARGX
43.6
49%
0.9
AU
CSL Ltd
ASX:CSL
10.9
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Navidea Biopharmaceuticals Inc
OTC:NAVB
Average EV/EBIT: 20.8
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.3
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.4
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
15.5
13%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
17%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
23%
0.6
NL
argenx SE
XBRU:ARGX
44.6
51%
0.9
AU
CSL Ltd
ASX:CSL
13.7
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett